A newly published clinical trial is set to reshape how the nutraceutical industry approaches NAD\u207a enhancement. In a peer-reviewed, randomized, double-blind, placebo-controlled study in the Journal of Functional Foods, researchers showed that the botanical complex BluNADBooster outperformed the long-standing benchmark NAD\u207a precursor, nicotinamide riboside (NR), across multiple healthy-ageing domains.The study demonstrated that BluNADBooster significantly improved biomarkers of mitochondrial health, energy metabolism, inflammation, cognition, physical performance, and quality of life. Notably, BluNADBooster increased blood NAD\u207a levels by 26.48%, surpassing NR alone, while the combination of BluNADBooster and NR achieved the greatest rise (31.76%). Unlike precursor-only strategies, BluNADBooster also modulated CD38 activity\u2014an age-related driver of NAD\u207a decline\u2014while delivering polyphenol-driven anti-inflammatory and cognitive benefits. These findings position BluNADBooster as a next-generation, plant-based approach to cellular energy, longevity, and proactive healthy ageing.<\/p>\n\n\n\n